Abstract

The humoral immune response to tumor-associated antigens in cancer patients can be used as the basis for diagnosing and monitoring the disease. Moreover, identification of the protein targets of such a response can serve as the basis for developing antigen-specific anticancer vaccines. This review discusses the main methods for identifying and studying tumor-associated antigens, recognized by serum antibodies, and also notes the problems facing researchers, which must be solved to introduce serologic antigen kits into the clinical diagnosis of cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call